Cytokinetics Q2 revenue falls as license revenue drops
CYTK•Outlook and guidance
Cytokinetics raised its 2026 GAAP R&D and SG&A expense guidance to $860 million-$890 million.
The company expects to submit a supplemental NDA for aficamten in non-obstructive HCM in Q4 2026. Cytokinetics also expects to launch MYQORZO in over five additional markets by H1 2027.
Drivers of the quarter and key details
- MYQORZO LAUNCH - Co said Q2 results were driven by commercial launch momentum for MYQORZO in the US and Germany, with expanding physician adoption and patient access.
- HIGHER LAUNCH COSTS - SG&A expenses increased due to costs associated with the commercial launch of MYQORZO and higher personnel-related costs.
- ABSENCE OF LICENSE REVENUE - Overall revenue declined as Q2 did not include license and milestone revenue, compared to $64.4 million in Q2 2025.
| Metric | Actual |
|---|---|
| Q2 Revenue | $28.62 million |
| Q2 Loss Per Share | $1.50 |
| Q2 Net Loss | $198.76 million |
| Q2 Operating Expenses | $207.80 million |
